(Albany, United States) As per DelveInsight’s assessment, globally, the Neuroendocrine Tumor pipeline constitutes 55+ key companies continuously working towards developing 60+ Neuroendocrine Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Neuroendocrine Tumor Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Neuroendocrine Tumor clinical trials studies, Neuroendocrine Tumor NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumor collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Neuroendocrine Tumor pipeline treatment landscape of the report, click here @ Neuroendocrine Tumor Pipeline Outlook

 

Key Takeaways from the Neuroendocrine Tumor Pipeline Report

• DelveInsight’s Neuroendocrine Tumor Pipeline analysis depicts a robust space with 55+ active players working to develop 60+ pipeline treatment therapies.
• The leading Neuroendocrine Tumor Companies working in the market include Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others
• Emerging Neuroendocrine Tumor Pipeline Therapies in the various stages of development include AlphaMedix, 177Lu-DOTA-EB-TATE, octreotide FluidCrystal® injection depot, Everolimus, CAPTEM (Capecitabine and Temozolomide), Pelcitoclax, Sunitinib, Lanreotide (Autogel formulation) and Temozolomide, Fosbretabulin tromethamine, and others
• On January 2023, ITM Solucin GmBH announced a study of phase 3 clinical trials for 177Lu-edotreotide PRRT and Everolimus. The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
• On March 2023, Ascentage Pharma Group Inc announced a study of phase 1 clinical trials for Pelcitoclax. APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents, indicating that APG-1252 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is intended for the treatment of patients with neuroendocrine tumors. The purpose of the phase 1b study to establish the maximum tolerated dose (MTD), and/or recommended phase 2 dose (RP2D). Preliminary efficacy and pharmacokinetic properties will be aslo evaluated.
• On April 2023, Clarity Pharmaceuticals Ltd announced a study of phase 2 clinical trials for 64Cu-SARTATE. The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.

 

Neuroendocrine Tumor Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells.

 

To explore more information on the latest breakthroughs in the Neuroendocrine Tumor Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Neuroendocrine Tumor Emerging Drugs Profile

• ITM-11: ITM Solucin
• Alphamedix: RadioMedix
• BI 764532: Boehringer Ingelheim

 

Neuroendocrine Tumor Pipeline Therapeutics Assessment

There are approx. 55+ Neuroendocrine Tumor companies which are developing the therapies for Neuroendocrine Tumors. The Neuroendocrine Tumor companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. phase III include, ITM Solucin.

 

Request a sample and discover the recent advances in Neuroendocrine Tumor Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Neuroendocrine Tumor Drugs and Companies

• AlphaMedix: Radiomedix Inc
• 177Lu-DOTA-EB-TATE: Molecular Targeting Technologies Inc
• octreotide FluidCrystal® injection depot: Camurus AB/Novartis
• Pelcitoclax: Ascentage Pharma Group Inc

 

Neuroendocrine Tumor Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Neuroendocrine Tumor Therapeutics Market include-

Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

 

Dive deep into rich insights for drugs for Neuroendocrine Tumor Pipeline, click here for Neuroendocrine Tumor Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Scope of the Neuroendocrine Tumor Pipeline Report

• Coverage- Global
• Neuroendocrine Tumor Companies- Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.
• Neuroendocrine Tumor Therapies- AlphaMedix, 177Lu-DOTA-EB-TATE, octreotide FluidCrystal® injection depot, Everolimus, CAPTEM (Capecitabine and Temozolomide), Pelcitoclax, Sunitinib, Lanreotide (Autogel formulation) and Temozolomide, Fosbretabulin tromethamine, and others
• Neuroendocrine Tumor Segmentation: Product Type, Molecule Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neuroendocrine Tumor Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Neuroendocrine Tumors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ITM-11: ITM Solucin
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Alphamedix: RadioMedix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BI 764532: Boehringer Ingelheim
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Neuroendocrine Tumors Key Companies
18. Neuroendocrine Tumors Key Products
19. Neuroendocrine Tumors – Unmet Needs
20. Neuroendocrine Tumors – Market Drivers and Barriers
21. Neuroendocrine Tumors – Future Perspectives and Conclusion
22. Neuroendocrine Tumors Analyst Views
23. Neuroendocrine Tumors Key Companies
24. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services